Prescriptive analytics, not just predictive analytics, will make a difference in patient outcomes, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
Prescriptive analytics, not just predictive analytics, will make a difference in patient outcomes, said John Frownfelter, MD, FACP, chief medical officer of Jvion.
Transcript
Is the future of healthcare predictive analytics?
Predictive analytics is essentially risk stratifying patients. That’s already going away and it’s going to become very passé, and I’ll tell you why. Predictive analytics—anyone can do a risk model now and then apply it to a population, and identify patients at risk for everything from who’s at risk from being admitted to the hospital to who’s at risk of not taking their medicine to who’s at risk for dying in the next 30 days. Ok great. But then what? What do you do with that information when you just know they’re high risk?
Oftentimes, these are patients that we already know that that’s likely to happen. And so it doesn’t add to clinical knowledge for a seasoned clinician. Secondly, if it is a patient that we way, “Ok, we’re going to do everything for these high-risk patients,” again, they may or may not be impactable. And then there are a number of patients in these risk models with just doing predictive modeling that the risk actually isn’t true and we’re throwing a lot of good resources after bad, if you will.
Prescriptive analytics isn’t just taking a risk model then, but it really is a different approach using artificial intelligence [AI], big data, and some different approaches that I won’t get into all the math on. But to understand patients holistically and to identify the patients, not only the risk, but again the nature of the risk and then ultimately, which particular interventions are going to change the outcome for that patient.
Now, that all sounds good. If you look at, “well, how do I compare these different approaches for relative benefit?” the first way you compare them is on performance of the model. Which one is better at predicting? Great. If you have a little bit more longevity, you can look at patient outcomes. And what we’re seeing with the application of AI is improved patient outcomes. We’re seeing reductions in hard end points. In oncology, we’re seeing reductions in patients who are admitted to hospice in the last 3 days of life. That’s a phenomenal thing for patients. We’re seeing reductions in emergency room visits and in hospitalizations. We’re seeing decreases in pain scores and a decrease in depression.
These are things by which not only oncology practices are held accountable, but patients care about. And we’re seeing the outcomes. That’s truly success, it isn’t math modeling and who has got a better performance from a model standpoint, but who is changing patient care.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More